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1 |  INTRODUCTION
3‐hydroxyisobutyryl‐CoA hydrolase (HIBCH) (a nuclear‐ 
encoded mitochondrial enzyme) deficiency is one of the rare 
inborn metabolism errors in valine's catabolism with an es-
timated incidence of about 1:128 000 in Asia. Main clinical 
manifestations include childhood neurodevelopmental and 
motor delay, dystonia and ataxia, which are associated with 
brain imaging abnormalities. Due to few cases which are re-
ported worldwide, the characteristics, genes, etc. are not well 
defined. Thus, it is important to pay attention to cases which 
are suspected of HIBCH deficiency.
We report a patient which has no positive family history 
of metabolism disorders or consanguineous marriage of par-
ents which have developmental delay and Leigh‐like abnor-
malities showing on magnetic resonance imaging (MRI), as 
HIBCH deficiency with elevated 3‐hydroxyisovaleric acid 
in urine and HIBCH mutation in whole‐exome sequenc-
ing. Two novel heterozygous missense variants (c.641C>T; 
p.Thr214Ile and c.913A>G; p.Thr305Ala), which are de-
tected in HIBCH gene (NM_014362.3), are responsible for 
hydrolysis of both 3‐hydroxyisobutyryl‐CoA (HIBYL‐CoA) 
and 3‐hydroxypropanoyl‐CoA, which are important in valine 
catabolism pathway. HIBCH deficiency, as a disorder of va-
line catabolism, should be considered in the differential di-
agnosis of Leigh‐like disease and/or organic aciduria. Due to 
the rare cases of this disorder, proper diagnosis, and attention 
to diagnostic clues are essential.
Mitochondrial disorders are rare generally, accounting for 
about 1:5000 births,1 half of which originate from mitochon-
drial or nuclear‐encoded defects of mitochondrial protein 
synthesis, which is caused by rare inborn metabolism errors2; 
3‐hydroxyisobutyryl‐CoA hydrolase (HIBCH) is a nuclear‐
encoded mitochondrial enzyme and its deficiency (OMIM 
#250620) impairs conversion of 3‐hydroxyisobutryl‐CoA to 
3‐hydroxy‐isobutyric acid, as the fifth step in valine catab-
olism, accumulating toxic valine metabolites that interfere 
with mitochondrial enzymes potentially.3,4
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We report a patient presenting with developmental delay, Leigh‐like abnormalities 
on MRI and elevated 3‐hydroxyisovaleric acid levels. Upon whole‐exome sequenc-
ing, he was diagnosed with 3‐hydroxyisobutyryl‐CoA hydrolase (HIBCH) defi-
ciency, and hence subjected to specific dietary treatment. HIBCH deficiency should 
be considered in the differential diagnosis of Leigh‐like disease and/or organic 
aciduria.
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This autosomal recessive disease is a very rare condition 
with an estimated incidence of 1 in 551 545 in Europeans to 
1 in 127 939 in South Asia.5 Since its introduction in 1982,6 
few cases have been reported worldwide, the results indi-
cated main clinical manifestations including neurodevelop-
mental and motor delay, dystonia and ataxia, in early infancy 
or within the first year of life.5,7,8 Magnetic resonance imag-
ing (MRI) shows a wide range of abnormalities, including 
involvement of the basal ganglia and cerebral peduncles with 
varying degrees of white matter atrophy.5,7 Nevertheless, the 
cerebral changes which are indicated on MRI or computed 
tomography (CT) scan cannot differentiate between mito-
chondrial encephalomyopathies which are caused by primary 
respiratory chain (RC) deficiencies; therefore, diagnosis is 
only established by genetic and molecular assessment.7
Yet, as few cases are reported in the literature so far, it is 
important to pay attention to a more common Neuro‐metabolic 
condition, which is called Leigh syndrome (OMIM #256000),8 
which has similar clinical features (infantile onset of progressive 
encephalopathy) and imaging characteristics (bilateral basal 
ganglia and white matter changes), which are caused mainly by 
defects in oxidative phosphorylation and may be accompanied 
with elevated lactic acid.9,10 Thus, most patients manifesting 
such symptoms, are anticipated as mitochondrial diseases, firstly 
are diagnosed as Leigh's disease, while HIBCH, as a much rarer 
condition, is not investigated typically.10 Accordingly, it is im-
portant to pay specific attention to HIBCH deficiency in patients 
manifesting Leigh‐like signs and symptoms.5,12 Furthermore, 
most studies have reported cases in siblings or children of par-
ents with consanguineous marriage5,14; in this paper, we report 
a patient which has no positive family history of metabolism 
disorders or consanguineous marriage of parents, manifesting 
developmental delay and Leigh‐like abnormalities based on 
MRI, diagnosed as HIBCH deficiency with elevated 3‐hydroxy-
isovaleric acid in urine and HIBCH mutation in whole‐exome 
sequencing (WES).
2 |  CLINICAL REPORT
The patient was the first child of healthy parents, without 
consanguineous marriage, which was born in Qom, Iran. He 
was born at 38 weeks of gestation after a normal pregnancy. 
Growth parameters were normal at birth time (birth weight: 
3000 g, birth height: 50 cm, and head circumference (HC): 
34 cm). Neonatal screening revealed no pathologies which 
was performed using tandem mass spectrometry. He only 
had a history of hospitalization due to neonatal jaundice.
At age of 15 months old, the child had recurrence attacks 
following febrile diseases with symptoms including weak-
ness, myoclonus, and eye nystagmus. The results of brain 
MRI which was requested for the patient at age of 2 years 
old revealed symmetric signal abnormalities of the basal 
ganglia, reminiscent of metabolic or mitochondrial disorders 
(Leigh‐like syndrome) without any structural brain anoma-
lies, myelination defect, or heterotopia (Figure 1).
At the age of 3.5 years old, the patient neither could 
walk independently, nor talk naturally (could not make a 
sentence). In physical examination, he exhibited hyperac-
tive deep tendon reflexes with general muscular hypotonia, 
which is a central coordination disorder, ataxia, dysme-
tria, convergent strabismus and nystagmus of the eyes, 
and growth parameters were delayed (Length: 90 cm (3%), 
weight: 12 kg (3%), and HC: 48.5 cm (15%)).
Further laboratory examinations revealed that plasma 
amino acids and plasma acylcarnitine profile were normal. 
The organic acid in the urine showed an elevated 3‐hydroxy-
isovaleric acid (110 mmol/mol creatinine, normal <44 mmol/
mol creatinine). Serum biotinidase activity was normal. Blood 
lactate and ammonia were normal in repeated measurements.
3 |  MOLECULAR GENETIC 
ANALYSIS
3.1 | DNA extraction
Blood samples were collected from the patient and his par-
ents in tubes containing ethylene diamine tetra acetic acid 
(EDTA). Genomic DNA was extracted from whole blood 
sample using Blood SV mini kit (GeneAll Biotechnology Co., 
LTD, Seoul, South Korea) according to the manufacturer's 
F I G U R E  1  Brain MRI at age 2 y showed bilateral high signal 
lesions in the globus pallidus
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instructions. Concentration and purity of DNA were assessed 
by using a microspectrophotometer before being used for 
PCR‐Sanger sequencing.
Another round of quality control for DNA sample was 
performed before using DNA for WES. Quantity of DNA 
was measured by PicoGreen (Invitrogen, Thermo Fisher 
Scientific, Waltham, MA, USA) using Victor3 fluorometry. 
DNA condition was assessed by gel electrophoresis.
3.2 | Polymerase chain reaction (PCR) and 
Sanger sequencing
All targets which were amplified by PCR and PCR products were 
purified using PCR SV mini kit (GeneAll Biotechnology Co., 
LTD). Sanger sequencing of PCR products was performed using 
Applied Biosystems 3500 Genetic Analyzer (Pishgam Biotech 
Co., Tehran, Iran). The obtained sequences were analyzed by 
comparing them to the reference human genome sequence.
3.3 | Whole‐exome sequencing
Library preparation was performed by using Agilent 
SureSelect Human All Exon V6 system (Agilent 
Technologies, Inc., Santa Clara, CA, USA) according to 
manufacturer's instructions. Libraries were sequenced by 
high‐throughput paired‐end sequencing using HiSeq 4000 
sequencing platform (Illumina Inc., San Diego, CA, USA). 
The sequencing was offered as a service by Macrogen Inc., 
Seoul, South Korea.
Sequencing short reads of 101‐base long were aligned 
to the reference human genome hg19 from UCSC genome 
browser (University of California, Santa Cruz, CA, USA) 
using the Burrows‐Wheeler Aligner (BWA) program. Variant 
calling and filtering were done using Genome Analysis Toolkit 
(GATK‐v3.4.0). Detected variants were annotated using 
SnpEff‐v4.1g software (Cingolani et al., 2012)11.
Then, proper filtering and interpreting a short list of 
variants in terms of pathogenicity were performed based 
on ACMG (American College of Medical Genetics and 
Genomics) guidelines for variant interpretation.
In order to evaluate the pathogenicity of novel variants, the 
potential effect of a given variant on the function or structure of 
the encoded protein was analyzed. The analysis was carried out 
based on conservation, physical properties of the amino acids or 
possible occurrence in regulatory or splicing motifs using bioin-
formatics tools. OMIM and PubMed were reviewed for previous 
publications which are related to the candidate causative gene.
4 |  RESULTS
Isovaleric Acidemia (IVA) was suggested as the possi-
ble diagnosis for the patient based on the analysis of urine 
organic acids that showed an elevated 3‐hydroxyisovaleric 
acid level and that serum biotinidase activity was normal. 
Therefore, PCR‐Sanger sequencing was used in order to 
analyze all exons and exon‐intron boundaries of IVD gene 
(NM_002225). No pathogenic variant was detected in this 
evaluation.
As no specific diagnosis was available, WES was used 
in order to evaluate all known exons and their flanking re-
gions. Total number of reads which are obtained from this 
sample was equal to 141 209 836. These reads generated total 
sequence of more than 14.26 gigabases that gave an average 
throughput depth about 235.9 for target regions; 99.9% of 
target regions had a coverage of more than 1X, and 98.9% 
showed the coverage of more than 10X.
By using WES, two heterozygous missense variants 
(c.641C>T; p.Thr214Ile and c.913A>G; p.Thr305Ala) were 
detected in HIBCH gene (NM_014362.3). Multiple lines of 
in silico obtaining from computational analysis support the 
deleterious effect of the variants on the gene or gene product.
Compound heterozygosity of detected variants was 
confirmed by trio PCR‐Sanger sequencing in the patient 
(Figure 2) and each of the parents. Evaluating the parents 
confirmed the presence of heterozygosity in his father for 
the variant c.641C>T and the presence of heterozygosity in 
his mother for the variant c.913A>G (Figure 2). Therefore, 
paternal and maternal variant origins were confirmed, with 
Trans configuration in the patient consistent with the ob-
served loss‐of‐function phenotype.
5 |  DISCUSSION
In the present study, we reported a 4 years old boy with devel-
opmental delay, including inappropriate walking and talking, 
and growth parameters (Percentile). Abnormalities showing 
in brain imaging at the age of two years old showed bilat-
eral high signal lesions in the globus pallidus. Nevertheless, 
patient was not diagnosed appropriately until the age of ap-
proximately 3.5 years old, when the child was suspected for 
having Isovaleric Acidemia after observing elevated urinary 
level of 3‐hydroxyisovaleric acid and serum biotinidase ac-
tivity that was normal. Afterward, for confirming diagnosis, 
he was referred for genetic counseling. As no pathogenic 
variant was detected in PCR‐Sanger sequencing, which was 
used to analyze all exons and exon‐intron boundaries of 
IVD gene (NM_002225), WES was performed in order to 
find out the cause of disease in the patient, and the results 
revealed that there are two heterozygous missense variants 
(c.641C>T; p.Thr214Ile and c.913A>G; p.Thr305Ala) in 
HIBCH gene (NM_014362.3), which are responsible for en-
coding proteins in hydrolysis of both 3‐hydroxyisobutyryl‐
CoA (HIBYL‐CoA) and 3‐hydroxypropanoyl‐CoA, and are 
important in valine catabolism pathway. Homozygote or 
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compound heterozygote mutations in HIBCH gene cause 
3‐hydroxyisobutryl‐CoA hydrolase deficiency (OMIM 
#250620) that is inherited in autosomal recessive manner. 
Both variants were novel and there was no previous report 
for their pathogenicity. They were absent in population's da-
tabases such as ExAc, 1000G, and dbSNP. Both were also 
absent in Pishgam Database of Genomic Variants in Iranian 
Population (Pishgam Biotech Co., Iran). Therefore, pater-
nal and maternal origins and Trans configuration of vari-
ants were confirmed in the patient. Based on the available 
evidence, we assumed these variants as the cause of disease 
in the patient.
Although manifestations of HIBCH deficiency overlap 
with other mitochondrial disorders, its management is differ-
ent and treating with carnitine and dietary valine and protein 
restriction appears to be beneficial. We started the treatment 
after definite diagnosis and the parents were introduced to a 
genetic counselor for future pregnancy.
In metabolic pathway of valine, first, valine changes to 
methylacrylyl CoA in three stages; then, methylacrylyl CoA 
changes to 3‐hydroxyisobutyryl‐CoA by crotonase, and in the 
next step, 3‐hydroxyisobutyryl‐CoA changes to 3‐hydroxy-
isovaleric acid by HIBCH and after one other step, it turns to 
the end product propionyl CoA finally 4 (Figure 3).
HIBCH (EC 3.1.2.4) is a highly specific mitochondrial 
enzyme in monomeric form and in case of its deficiency, 
the toxic substrates accumulate in mitochondria that inter-
fere with mitochondrial enzymes and deplete mitochondrial 
pools of cysteine, glutathione, thioredoxin, CoA, or lipoic 
acid.3,12 The accumulated substrate of HIBCH can be de-
tected in urine as 3‐hydroxyisovaleric acid conjugates,13,14 
like in conditions which there is an increased fatty acid 
oxidation with elevated activity of short‐chain enoyl‐CoA 
hydratase (SCEH) that lead to an increased production of 3‐
hydroxyisovaleric acid.7 In our case, similarly, the analysis 
of urine organic acids showed an elevated urinary level of 
3‐hydroxyisovaleric acid and IVA which was suggested as 
the possible diagnosis for the patient.
As far as we are concerned, <10 cases with HIBCH de-
ficiency have been reported, all of which reported cases 
with consanguineous parents or positive family history, 
while our patient had none of these conditions. Reuter et al10 
and Loupatty et al15 reported diagnosis of HIBCH defi-
ciency in the first child of healthy consanguineous parents, 
and Ferdinandusse et al reported two brothers, which were 
born from Pakistani parents which were distant relatives.16 
Nevertheless, our patient neither had family history of any 
metabolism disorder, nor was the child of a consanguineous 
F I G U R E  2  Sanger sequencing 
chromatograms of the HIBCH mutated 
regions in the patient (top) showing the 
heterozygous c.641C>T (A) and c.913A>G 
(B) variants, the patient's father (middle) 
showing the heterozygous c.641C>T variant 
(A) and the normal homozygous c.913A 
(B), and the patient's mother (bottom) 
showing the normal homozygous c.641C 
(A) and the heterozygous c.913A>G variant 
(B)
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marriage; although he was also the first child of the family, 
like the patients which were reported by Loupatty et al15 and 
Reuter et al,10 but contrary to them, our patient's parents did 
not have a consanguineous marriage.
Notably, studies have reported similar clinical symp-
toms, including different neurodegenerative disorders, 
nystagmus, and motor disorders, in addition to abnor-
malities in the basal ganglia showing in MRI, but as they 
include a wide range of symptoms with several differen-
tial diagnoses,15,17 further laboratory examinations are re-
quested to differentiate between Leigh‐like mitochondrial 
diseases. However, laboratory tests do not seem to have 
similar results between the cases which were reported; for 
example, some have reported normal blood lactate and 
ammonia levels,15 which is similar to our study, while oth-
ers reported elevated blood lactate.5 According to Reuter 
et al, RC enzymes were at borderline in skeletal muscle 
and diagnosis was confirmed by WES (homozygous one‐
base‐pair insertion in HIBCH)10; similarly in the present 
case, that WES was used for final diagnosis. According to 
Ferdinandusse et al RC enzymes were deficient in skeletal 
muscle and diagnosis was confirmed by using spectropho-
tometric enzyme assay (low HIBCH activity) in cultured 
skin's fibroblasts which were taken from both brothers 
and direct Sanger sequence analysis which demonstrated 
a novel homozygous missense mutation (c.950G>A; 
p.Gly317Glu) in the HIBCH gene.16 In the present study, 
WES revealed two novel heterozygous missense variants 
(c.641C>T; p.Thr214Ile and c.913A>G; p.Thr305Ala) in 
the patient.
Although all the cases which are described above are di-
agnosed as HIBCH deficiency in childhood or early infancy, 
there are few cases which are reported in adult and adoles-
cents with mild symptoms.17
Very few cases of HIBCH deficiency have been reported 
worldwide and most cases, if diagnosed, they were misdi-
agnosed as other mitochondrial disorders like Leigh's syn-
drome. Thus, it is essential to report any case with HIBCH 
deficiency in order to add to the physicians’ knowledge about 
this disorder. In this paper, we reported a patient which was 
a rare case regarding two dimensions: first, the child nei-
ther had a family history of metabolism disorders nor con-
sanguineous marriage of parents, second, he had two novel 
heterozygous missense variants (c.641C>T; p.Thr214Ile and 
c.913A>G; p.Thr305Ala), which were detected in HIBCH 
gene (NM_014362.3). Similar to other cases which are re-
ported, clinical and brain imaging results were similar to pre-
vious reports, and HIBCH mutation was confirmed by WES. 
Due to the rare cases of this disorder, proper diagnosing and 
paying attention to diagnostic clues are essential.
6 |  CONCLUSIONS
HIBCH deficiency, as a disorder of valine catabolism, should 
be considered in the differential diagnosis of Leigh‐like dis-
ease and/or organic aciduria. Due to the rare cases of this dis-
order, proper diagnosing and paying attention to diagnostic 
clues are essential.
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